Paeds Cases · paediatric-dermatology
Negotiate the acne treatment plan with an adolescent — OSCE
OSCE communication and shared decision-making station: explaining the moderate inflammatory acne to a withdrawn 15-year-old and his mother, agreeing the stepwise plan of the topical retinoid and the benzoyl peroxide and the oral doxycycline, counselling the adherence and the photoprotection, naming the antibiotic stewardship, addressing the psychosocial impact and the scarring worry, and setting the clear pathway to the isotretinoin.
On this page & tools
Target exams
Communication framework
Engage the adolescent first, then the parent. Address the young person by name and ask, in their own words, what bothers them most and what they have already tried. The withdrawal from swimming is the distress you must name and relieve, and the young person's own goals — not the mother's scarring worry alone — frame the plan you agree. Acknowledge the mother's anxiety about the scarring as legitimate, because the early atrophic marks are the real risk, and the early and the effective treatment is the prevention. [2] [9]
Explain the disease in plain language. Name the four drivers — the hormone-driven oil, the skin germ that feeds on it, the pore that blocks, and the redness that flares when the pore bursts — so the family understands why the treatment combines several drugs rather than a single tablet. Explain that the comedonal and the inflammatory split means the topical retinoid unblocks the pore and the benzoyl peroxide and the oral antibiotic calm the inflammation. Set the realistic timeline: the improvement is judged at six to eight weeks, not days, because the pore cycle is slow. [1] [2]
Agree the plan and the adherence. Offer the adapalene 0.1 per cent at night to the whole area, the benzoyl peroxide 2.5 per cent by day, and the oral doxycycline 50 to 100 mg once daily for three months. Explain the antibiotic stewardship in family terms: the antibiotic never works alone, it always travels with the benzoyl peroxide, and the course is capped at three months so the skin germ does not grow resistant. Counsel the dryness, the photosensitivity, and the sunscreen, and agree the application to the whole area, not just the spots, because the invisible microcomedone is the target. [1] [7]
Address the miracle-tablet expectation honestly. Explain that the oral isotretinoin is the powerful option for the severe, the scarring, and the refractory disease, but it is not the quick fix: it needs the months, the blood monitoring, and (in a female) the strict contraception because it harms a pregnancy. Set the clear pathway: try the three-month combination plan first, and if the nodules, the scarring, or the resistance persist, the dermatology referral and the isotretinoin are the next step. This honesty builds the trust and the adherence. [2] [9]
Close with the safety-net and the follow-up. Review at six to eight weeks for the topical response and at three months for the antibiotic decision, screen the mood at each visit, and name the early escalation triggers: the worsening nodules, the scarring, and the distress. Reassure the young person that the effective treatment is the route back to the swimming, and that the plan is theirs to own. [1] [9]
Marking domains
- Information gathering and rapport (25 per cent). Engages the adolescent first, screens the psychosocial impact, and acknowledges the parental anxiety about the scarring. [2]
- Explanation and shared decision-making (30 per cent). Explains the four drivers and the comedonal versus the inflammatory split in plain language, sets the realistic timeline, and negotiates the plan the young person will own. [1]
- Clinical accuracy (25 per cent). Names the correct regimen — the adapalene and the benzoyl peroxide, the oral doxycycline with the stewardship — and the honest pathway to the isotretinoin. [1] [7]
- Safety-netting and follow-up (20 per cent). Sets the review intervals, the mood screen, and the escalation triggers, and closes the loop with the adolescent. [9]
References
- [1]Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris Journal of the American Academy of Dermatology, 2024.PMID 38300170
- [2]Eichenfield DZ, Sprague J, Eichenfield LF. Management of Acne Vulgaris: A Review JAMA, 2021.PMID 34812859
- [7]Zhu C, Wei B, Li Y, et al. Antibiotic resistance rates in Cutibacterium acnes isolated from patients with acne vulgaris: a systematic review and meta-analysis Frontiers in Microbiology, 2025.PMID 40535003
- [9]Gieler U, Gieler T, Kupfer JP. Acne and quality of life - impact and management Journal of the European Academy of Dermatology and Venereology, 2015.PMID 26059729